Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NovAliX Appoints CSO

Published: Wednesday, October 17, 2012
Last Updated: Wednesday, October 17, 2012
Bookmark and Share
Appointment of Dr Luc Van Hijfte as CSO drug discovery.

NovAliX has announced that it has appointed pharma research executive Dr Luc Van Hijfte as CSO Drug Discovery.

Dr. Van Hijfte brings a wealth of experience in pharmaceutical research with over 25 years spent in drug discovery.

He joined from Janssen, a J&J company, where he served as Head of Medicinal Chemistry EU with responsibility over European based chemical sciences and ADMET.

During this tenure, that included responsibility as site head of the Janssen-Cilag Research Center in Val de Reuil, Dr Van Hijfte has been privileged to contribute to several successful projects with numerous programs entering into clinical development in the areas of Neurosciences, Oncology and Infectious Diseases, with compounds up to phase III level, the most advanced being the anti-tuberculosis compound TMC 207 currently being reviewed by the FDA for market authorization.

Prior to that Dr Van Hijfte had responsibilities at Hoechst Marion Roussel, subsequently at Sanofi as Head of chemistry of the Strasbourg research center.

Luc Van Hijfte earned his PhD in organic synthetic chemistry from the University of Gent under the supervision of Pr. M. Vandewalle, and has completed a post-doctoral training at the University of California, Santa Barbara, in the laboratory of Pr. R.D. Little.

Dr Van Hijfte, who is sharing the vision of the company founders, believing in the relevance of biophysical sciences for drug discovery commented, "I have been impressed by the scope and scale of the biophysical technologies NovAliX has assembled. That was a compelling argument to join the company and have the opportunity to run fragment-based discovery programs".

Both, Denis Zeyer, CEO, and Jean-Paul Renaud, CSO Science & Technology, and founding members of the company are enthusiastic about that addition to the team. "This is a defining moment for our company. Since inception, we have been concentrating on the development of our scientific capabilities in chemistry and biophysics, using a combination of internal technology developments and external sourcing including corporate acquisitions and academic collaborations. With Luc Van Hijfte now joining the team, we add significant pharmaceutical research leadership to our small molecule discovery capabilities".


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NovAliX Enters into Alliance with Kyowa Hakko Kirin
Companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
Monday, January 14, 2013
NovAliX and Servier Collaborate in Early Discovery Research Program
Under the terms of Graffinity agreement, a NovAliX subsidiary, will be responsible for the discovery of specific small molecule lead candidates for a novel exploratory target chosen by Servier.
Wednesday, October 10, 2012
NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the CBS.
Friday, September 16, 2011
NovAliX and Galapagos Collaborate in Osteoarthritis Discovery Research Program
NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos.
Monday, August 29, 2011
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!